March 10, 2020 / 1:07 PM / a month ago

BRIEF-Krystal Biotech Reports 2019 Financial Results And Business Progress

March 10 (Reuters) - Krystal Biotech Inc:

* KRYSTAL BIOTECH REPORTS 2019 FINANCIAL RESULTS AND BUSINESS PROGRESS

* KRYSTAL BIOTECH - PHASE 3 TRIAL OF B-VEC (BEREMAGENE GEPERPAVEC, PREVIOUSLY “KB103”) TO TREAT DYSTROPHIC EPIDERMOLYSIS BULLOSA TO START IN 1H 2020

* KRYSTAL BIOTECH INC - INTERIM RESULTS ON PHASE 1/2 CLINICAL STUDY ON KB105 TO BE ANNOUNCED IN 1H 2020

* KRYSTAL BIOTECH - PLANNED FILING OF TWO INVESTIGATIONAL NEW DRUG APPLICATIONS , ONE FOR RARE SKIN DISEASE AND ANOTHER FOR AN AESTHETIC SKIN INDICATION, IN 2H 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below